There are multiple chapters near you. Select your preferred chapter.

The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals has unveiled new data underscoring the importance of early ...

Askanase, MD, MPH, shares potential highlights for the upcoming ACR Convergence 2024 and how ... results — one for obinutuzumab in lupus nephritis and another for dapirolizumab in systemic ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and ...

WASHINGTON -- Lupus nephritis (LN) diagnosis could improve greatly if early results with a multimarker urine test are ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK ...

We are proud to share data and analyses, including clinical biomarker data, at ACR that support the potential ... refractory class III or class IV lupus nephritis (LN). Adicet is exploring the ...